pmid,title,journal,year,drug,disease
36879894,VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia.,Case reports in hematology,2023,Ruxolitinib,Pulmonary Embolism
36555286,"Inhibition of JAK1,2 Prevents Fibrotic Remodeling of Pulmonary Vascular Bed and Improves Outcomes in the Rat Model of Chronic Thromboembolic Pulmonary Hypertension.",International journal of molecular sciences,2022,Ruxolitinib,Pulmonary Embolism
35466415,Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.,British journal of clinical pharmacology,2022,Ruxolitinib,Pulmonary Embolism
34120321,Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.,Drug safety,2021,Ruxolitinib,Pulmonary Embolism
29508628,Drug-associated pulmonary arterial hypertension.,"Clinical toxicology (Philadelphia, Pa.)",2018,Ruxolitinib,Pulmonary Embolism
29196988,Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.,Drug safety,2018,Ruxolitinib,Pulmonary Embolism
28457008,A life-threatening ruxolitinib discontinuation syndrome.,American journal of hematology,2017,Ruxolitinib,Pulmonary Embolism
